Inventory Control Manager
Centessa Pharmaceuticals
Inventory Control Manager
Centessa Pharmaceuticals
Clinical-stage pharma with asset-centric model
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead investigational candidate – cleminorexton (formerly ORX750) – is being developed for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. Centessa's OX2R agonist portfolio includes additional clinical and preclinical-stage assets with potential utility across a broader range of neurological, neurodegenerative, and neuropsychiatric conditions.
Headquartered in Boston, Massachusetts, Centessa was recognized as a Great Place to Work® in 2026.
Description of Role
Centessa is seeking an Inventory Manager, Supply Chain contractor to own inventory planning, control, and reconciliation across the company's outsourced clinical supply network, including investigational product (IP), comparators, and ancillary materials held at third-party depots, CMOs/CDMOs, and distribution partners. This role ensures accurate, real-time visibility into inventory levels, drives forecast accuracy, and partners closely with external vendors and internal Clinical Supply, Quality, and Finance teams to prevent stockouts, minimize waste, and support uninterrupted trial execution. Reporting to Senior Director, Clinical Supply Chain, this individual will maintain accurate inventory records across systems (e.g., IRT, ERP), lead regular reconciliation cycles with vendors, and identify opportunities to strengthen inventory controls in a fast-paced, vendor-dependent environment.
Key Responsibilities
Inventory Planning & Forecasting
Inventory Control & Systems Management
Vendor & CMO Coordination
Reporting & Continuous Improvement
Qualifications
Compensation
The hourly range for this position is $55.00 to $80.00 per hour. Individual compensation within this range will be determined based on a variety of factors, including qualifications, skills, relevant experience, and job knowledge.
Contractors engaged through Centessa are employed through a third-party agency that serves as the employer of record and provides access to a comprehensive benefits package. Eligible contractors may enroll in medical plans, including PPO and EPO options, as well as dental and vision coverage after 30 days. Additionalperks, such as a 401(k), wellness programs, and other discounts, may also be available to eligible contractors.
Work Location
The Inventory Control Manager, Supply Chain (contractor) is a remote role based in the US.
POSITION: Full-Time, Exempt
EEOC Statement: Centessa Pharmaceuticals, a wholly owned subdisary of Eli Lilly and Company believes in a diverse environment and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion, or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. We will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.
Please note: We will not assign referral rights for any unsolicited resumes from recruitment agencies.
Clinical-stage pharma with asset-centric model
Centessa Pharmaceuticals is a clinical-stage biotechnology company built from ten autonomous subsidiaries that share centralized infrastructure under an asset-centric hub-and-spoke model. Its lead programs include ORX750, an oral orexin receptor 2 (OX2R) agonist for sleep-wake disorders, and an early-stage immuno-oncology effort based on the LockBody antibody platform. ORX750 aims to improve daytime wakefulness and cognitive function by activating the orexin pathway; LockBody uses engineered antibodies to target cancer more effectively. The company funds development through equity, debt, and partnerships and seeks regulatory approval and commercialization of its sleep-disorder asset while expanding its oncology portfolio.
Explore more opportunities at Centessa Pharmaceuticals